Jacobs Levy Equity Management’s UroGen Pharma URGN Stock Holding History

Jacobs Levy Equity Management’s Portfolio URGN Stock Details URGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$762K	Sell	20,696 -11,813	-36%	-$320K	﹤0.01%	755
2026 Q1	$585K	Sell	32,509 -6,874	-17%	-$138K	﹤0.01%	795
2025 Q4	$922K	Buy	39,383 +18,007	+84%	+$391K	﹤0.01%	694
2025 Q3	$426K	Buy	+21,376	New	+$384K	﹤0.01%	840
2021 Q4	–	Sell	-21,530	Closed	-$362K	–	1078
2021 Q3	$362K	Buy	21,530 +7,982	+59%	+$127K	﹤0.01%	911
2021 Q2	$207K	Buy	+13,548	New	+$245K	﹤0.01%	983

Other funds holding URGN

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Jacobs Levy Equity Management's URGN Position: Q2 2026 in Review

Jacobs Levy Equity Management reduced its UroGen Pharma (URGN) stake by 36% in Q2 2026, selling an estimated $320K and leaving 20,696 shares worth $762K. The position accounts for ﹤0.01% of the portfolio, ranked #755.

Jacobs Levy Equity Management first reported a position in URGN in Q2 2021 and has held it in 6 quarters since. The position peaked at $922K in Q4 2025. 190 funds tracked by Wall St. Rank hold URGN as of Q2 2026.

Jacobs Levy Equity Management held 20,696 shares of UroGen Pharma worth $762K as of Q2 2026.
Jacobs Levy Equity Management sold 11,813 UroGen Pharma shares in Q2 2026, an estimated $320K.
UroGen Pharma made up ﹤0.01% of Jacobs Levy Equity Management's portfolio in Q2 2026, its #755 holding.
Jacobs Levy Equity Management first reported a position in UroGen Pharma in Q2 2021 and has held it in 6 quarters since.
Jacobs Levy Equity Management's UroGen Pharma position peaked at $922K in Q4 2025.
190 funds tracked by Wall St. Rank held UroGen Pharma as of Q2 2026.

Based on Jacobs Levy Equity Management's 13F filing for Q2 2026, filed 14 Aug 2026.